222 results about "Immune correlates" patented technology

The invention provides an application of a compound Aldometanib in preparation of a medicine for preventing and treating immune-related adverse reactions and diseases. Based on the first discovered prevention and treatment effects of Aldometanib on fatal immune hepatitis, immune myocarditis, pneumonia and enteritis, the invention specifically discloses application of Aldometanib in preparation of drugs for prevention and treatment of immune-related adverse reactions and diseases, and the main mechanism is that Aldometanib activates immune cells AMPK, enhances catabolism of immune cells, promotes immune cell apoptosis, promotes immune cell apoptosis, and improves immune cell apoptosis. The anabolism of the immune cells is inhibited, so that the expression of effector factors of the immune cells is controlled, and inflammatory factor storm is inhibited. Aldometanib has the effects of preventing the occurrence of immune-related adverse reactions and diseases, and inhibiting the attack levels of the immune-related adverse reactions and diseases, so that non-lethal and lethal injuries caused by an immune system to body organs are reduced.

The invention relates to the technical field of microorganisms, and provides Witzia ciliaris KY009 (preservation number is CGMCC (China General Microbiological Culture Collection Center) NO. 33480) and Clostridium butyricum KY002 (preservation number is CGMCC NO. 33478), and the two strains are separated from an excrement sample. Experiments prove that the two strains can obviously improve the sperm quality and quantity, regulate the sex hormone level, improve the intestinal inflammation symptom and regulate the expression of related inflammatory factors. The invention also provides a composition containing the two strains, wherein the composition comprises a food composition, a pharmaceutical composition, a health-care product composition, a functional microbial agent and the like. The compositions are useful for improving reproductive health, modulating sex hormone levels, treating intestinal inflammation and promoting mucosal repair, and alleviating metabolic and immune related diseases. The strain and the composition provided by the invention have wide application prospects in the fields of medicines, foods and health-care products.

The invention discloses a method for generating a personalized vaccination scheme of a rabies vaccine in combination with an electronic medical record, and relates to the technical field of intelligent vaccination management, and the method comprises the following steps: extracting all structured feature information and unstructured feature information related to immune function evaluation in the electronic medical record of a patient, and constructing a feature data original mapping table; according to the method, by constructing the feature mapping table, the conflict relation matrix and the propagation path diagram, the logic conflict of the immune related information in the electronic medical record is accurately identified, the conflict intensity is quantified, the risk index is generated, and then the inoculation strategy path of the main feature and the alternative feature is dynamically adjusted. According to the method, the adaptability and fault-tolerant ability of the system to multi-source heterogeneous medical data are improved, decision deviation caused by feature conflicts is effectively avoided, the scientificity and safety of a personalized vaccination scheme of the rabies vaccine are enhanced, and the method has remarkable clinical and public health values.

The invention relates to the technical field of biomedicine, in particular to a method for constructing a plasma ctDNA organ distribution characteristic spectrum of advanced colorectal cancer. The method comprises the following steps: collecting a peripheral blood sample at multiple time points, separating plasma by adopting a double-centrifugal method, and extracting circulating tumor DNA (Deoxyribose Nucleic Acid); carrying out whole exome sequencing based on ctDNA to obtain genome variation information and calculating variation allele frequency, and synchronously detecting the expression quantity of immune-related proteins by adopting an Olink proteomics technology; integrating the genome data, the protein expression data and the clinical pathological features, and constructing a multi-dimensional feature data matrix; and taking the organ metastasis condition confirmed by iconography as a supervision label, training a model by applying a machine learning algorithm, screening key prediction factors, constructing a quantitative prediction model, and finally generating a visual organ metastasis tendency prediction map. According to the method, early and accurate prediction of the advanced colorectal cancer organ metastasis tendency is realized through multi-omics data collaborative analysis and machine learning modeling.

The invention provides a probiotic composition as well as a preparation method and application thereof. The composition is prepared from lactobacillus rhamnosus GG, lactobacillus acidophilus NCFM, an anti-IL-4R alpha monoclonal antibody, an inulin-beta-glucan compound and sodium alginate-chitosan microspheres. The composition regulates immune balance through a specific probiotic strain, blocks an IL-4 / IL-13 signal channel in combination with an anti-IL-4R alpha monoclonal antibody, and improves viable bacterium stability and bioavailability through a microsphere delivery technology. The probiotic composition shows a remarkable anti-allergic effect in an atopic dermatitis mouse model, and can reduce the serum IgE level, reduce the skin inflammatory response and reduce the STAT6 phosphorylation level. The probiotic composition disclosed by the invention has a wide application prospect in the aspect of treating atopic dermatitis and other immune-related diseases.

Provided are a novel modified side chain, and a preparation method therefor and a use thereof. In particular, provided are a modified side chain as represented by general formula (I), and a preparation method therefor, a pharmaceutical composition containing same, and a use thereof in the preparation of drugs for treating cancer, infections, neuropsychiatric diseases, cardiovascular diseases, endocrine diseases, and immune-related diseases.

A composition may be prepared by applying only an electric stimulus to a stem cell aggregate without introducing externally derived growth factors, etc. The composition has the advantage of remarkably reducing medical expenses because it can be prepared without using expensive growth factors. In addition, the composition may be used for treatment of a cartilage-related disease and does not express COL2, which is a mature chondrocyte marker, as compared to the conventional cells prepared for treating a cartilage-related disease and, thus, has the advantage of less immune-related side effects than mature cells.

The subject matter described here relates to anti-PD-1 x anti-IL-25 bispecific antibodies. In certain embodiments the bispecific antibody is used for the treatment or prevention of cancer. In certain embodiments the bispecific antibody is used for the treatment or prevention of breast cancer. In some embodiments, the bispecific antibody limits immune related adverse events.

The invention discloses a chimera for targeted degradation of immune protein. The chimera is formed by connecting a ligand of E3 ligase with a ligand of IDO protein through a linker. The invention also discloses a preparation method and application thereof. According to the present invention, a ligand capable of degrading immune-related protein-indoleamine 2, 3-dioxygenase (IDO) is coupled with a ligand of E3 ligase through a linker to construct the PROTAC capable of being used for tumor immunotherapy; the molecule can specifically degrade indoleamine 2, 3-dioxygenase, so that the effects of tumor targeting and immunotherapy are achieved, and the maximum killing effect on tumor cells and tissues is achieved.

The invention discloses a construction method of immune-related key gene prognosis indexes of metastatic melanoma and related equipment, and belongs to the field of bioinformatics, the method comprises the following steps: obtaining an immune-related differential expression gene list, and constructing a weighted gene co-expression network to divide gene modules, two gene modules with the highest correlation degree with the matrix score and the immune score are screened out, and gene intersection is taken to recognize immune related key genes; and determining immune-related key genes significantly related to the lifetime, and sequentially screening through univariate Cox regression and LASSO regression to obtain genes of which the regression coefficients are not zero so as to construct and obtain immune-related key gene prognosis indexes of metastatic melanoma. The method can solve the problems that in the prior art, when a prognosis index is constructed, an immune-related gene pair is only determined by an LASSO regression coefficient, key disease treatment genes are difficult to recognize, too many immune-related genes are contained, and clinical application convenience is low.

Methods are disclosed related to identifying small molecule metabolites that serve as biomarkers of immune related adverse events (irAEs). In embodiments, treatments are disclosed that reduce the likelihood or prevent irAEs.

The invention discloses a preparation method of mesenchymal stem cells for resisting ovarian granular cell aging. The preparation method comprises the following steps: providing umbilical cord blood stem cells; carrying out induced culture on the umbilical cord blood stem cells, collecting a supernatant after the culture is completed, and separating the supernatant to obtain an exosome; providing mesenchymal stem cells, and performing induced culture on the mesenchymal stem cells by adding the exosome, so as to obtain the required mesenchymal stem cells for resisting ovarian granular cell senescence. According to the preparation method of the mesenchymal stem cells for resisting ovarian granular cell senescence, the mesenchymal stem cells induced by the umbilical cord blood stem cell exosome can be prepared, and the mesenchymal stem cells can be used for treating premature ovarian failure in a whole body vein use mode. The umbilical cord mesenchymal stem cells induced by the stem cell exosome can exert a better immune regulation function, regulate the balance of an immune system and reduce immune-related inflammation and injury so as to delay the senescence of ovarian granular cells.

The invention relates to the technical field of immune functions, in particular to a construction method of a microRNA regulation and control network for influencing calf immunity establishment. According to the method, the expression profiles of microRNA in colostrum and finished milk are obtained, the microRNA with high expression and obvious difference in colostrum compared with the finished milk is found, target gene prediction is carried out on the differentially expressed microRNA, gene annotation and enrichment analysis are carried out on the obtained target gene, the target gene enriched by the MAPK pathway related to immunoregulation in the enrichment analysis result is screened, and the immunoregulation related MAPK pathway related to the immunoregulation is screened to obtain the immunoregulation related MAPK pathway related to the immunoregulation related to the immunoregulation related to the immunoregulation related to the immunoregulation related to the immunoregulation related to the immunoregulation related to the immunoregulation. And a network regulation relation graph of the immune-related target gene and the microRNA regulated by the immune-related target gene is obtained, so that the key node target gene regulated by the microRNA in milk in the MAPK pathway and the correlation between the key node target gene and the microRNA are screened out, and a technical support is provided for further research and development of feed additives or regulating agents for industrially improving the immunity of the calves.

The invention relates to the technical field of bioengineering, in particular to a preparation method of a probiotic and exosome preparation applied to immunoregulation. The probiotics and the umbilical cord stem cell exosome are combined for use, the immune regulation effect is enhanced from multiple targets and multiple ways, the immune function of the body is improved, the exosome carries a specific molecular marker and acts on immune cells in a targeted mode, precise immune regulation is achieved, and the preparation is in an oral form and convenient to use; the exosome is extracted from umbilical cord stem cells, has no pathogenicity and immunogenicity, and is low in adverse reaction risk after being used for a long time, and the prepared combined preparation can be used for treating and preventing various immune-related diseases, and also can be used for daily conditioning of people with low immunity and improving the body resistance; meanwhile, the combined preparation adopts micro-capsule embedding, so that the probiotics can be effectively protected from gastric acid and bile erosion, the survival rate and colonization efficiency of the probiotics in intestinal tracts are improved, the immunoregulation effect is further enhanced, and the combined preparation is convenient to store and transport and has a good application prospect.

The invention relates to application of SMAD6 in auxiliary diagnosis and prognosis evaluation of TGCT (Transforming Growth Computed Tomography). According to the invention, a novel TGCT prognosis biomarker (SMAD6) is identified through difference analysis, Cox regression and survival analysis on the basis of a TGCT sample in multiple centers. Subsequently, the expression level of SMAD6 in normal testicular tissues and TGCT is evaluated through immunohistochemical staining. Finally, the relationship between the SMAD6 and biological characteristics, mutation landscape, immune cell infiltration and immunotherapy response is also studied. The invention defines that SMAD6 is a risk factor of poor TGCT prognosis. An immunohistochemical result shows that the SMAD6 is highly expressed in the TGCT tissue. GSEA shows that SMAD6 is related to activation of tumor-related pathways and inhibition of immune-related pathways. In addition, high SMAD6 expression is associated with lower CD8 + T cell infiltration, while patients with low SMAD6 expression gain more benefits in immunotherapy. The invention fully reveals the potential of SMAD6 as a TGCT prognosis and immunotherapy reaction biomarker, and provides a new scientific basis and theoretical basis for personalized treatment of TGCT.

The present invention relates to a method for identifying immune-related microorganisms in colorectal cancer based on multi-omics features, and belongs to the field of biomedicine technology. The method includes analyzing the diversity and composition of intestinal flora in colorectal cancer patients and healthy controls; identifying intestinal microorganisms significantly associated with patients through the LASSO algorithm; selecting characteristic intestinal microorganisms of colorectal cancer by the SVM-RFE method; obtaining overlapping genes between the two algorithms, and incorporating the overlapping genes into ROC and DCA analysis verification; the method includes screening key microorganisms for immune regulation, predictive analysis of immune-related intestinal microbial functions, analysis of immune-related microorganisms and immune microenvironment, and prediction of the mechanism of action of immune-related intestinal microorganisms; the method of the present invention can screen out key microorganisms with immune regulatory effects in colorectal cancer, laying the foundation for studying the mechanism of action of intestinal flora and formulating personalized precision medication plans.

The invention belongs to the technical field of biological medicine, and relates to pharmaceutical application of an oxidative phosphorylation inhibitor, in particular to application of the oxidative phosphorylation inhibitor in preparation of an immunomodulatory drug, and the immunomodulatory drug has the advantages that the function damage of newborn myeloid-derived suppressor cells caused by antagonism BCG (bacillus calmette guerin) vaccination is inhibited, and the immunomodulatory effect is improved. The compound is used for preventing or treating neonatal immune-related diseases caused by bacillus calmette guerin vaccine inoculation. The invention finds that the BCG can cause damage to the immunosuppression function of the MDSC of the suckling mouse through up-regulation oxidative phosphorylation, and the negative effect caused by inoculation of the BCG can be reversed by using the OXPHOS inhibitor, so that the immunosuppression function of the MDSC of the suckling mouse is successfully recovered in an in-vivo and in-vitro model, and the immune-related adverse reaction caused by inoculation of the BCG is expected to be improved.

Provided herein is a method for inspecting irAE enteritis, comprising a detection step for detecting an antibody that immunologically reacts with a fragment or all of integrin [alpha] v [beta] 6 in a sample as an indicator of ulcerative colitis-like irAE enteritis.

The invention relates to the technical field of primary local hyperhidrosis, in particular to a biomarker for detecting primary local hyperhidrosis and application of the biomarker, and the biomarker comprises but is not limited to one or more of the ratio of Th17 cells to Treg cells, IL-17A, IL-6, ROR gamma t and FoxP3. According to the invention, a multi-dimensional detection system covering PFH core pathological links (immune disorder, hyperactivity of sympathetic nerves and hyperfunction of sweat gland) is constructed by integrating immune related markers such as Th17 / Treg cell ratio, IL-17A, IL-6, ROR [gamma] t, FoxP3 and the like and combining the concentrations of peripheral blood epinephrine (E) and noradrenaline (NE) and the gene expression levels of sweat gland tissues AQP5 and Cacna1c. And a potential molecular target is provided for developing a novel therapeutic strategy (such as specific blocking of an IL-17 signal channel or enhancement of a Treg function) of a targeted Th17 / Treg axis.

Compounds that inhibit PI3Kγ, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3Kγ.

The invention relates to the technical field of medical chemistry and tumor treatment, in particular to application of a novel NOX4 inhibitor ZZU026 and derivatives thereof in tumor resistance and immune response change. The preparation method of the ZZU026 comprises the following steps: replacing N, N-dimethylamino on a benzene ring of GKT137831 with morpholinyl; methoxyl is introduced into the core skeleton. The ZZU026 has a remarkable inhibiting effect on NOX4, has the functions of inhibiting tumor growth, new vascularization and immune-related diseases, regulating and controlling polarization of macrophages and the like, and can inhibit phenotype transformation of macrophages from M1 to M2 and finally inhibit proliferation and immune escape of lung cancer cells; the ZZU026 and the derivatives thereof can be prepared into drugs, health care products, tablets, particles, capsules, oral liquid or injection, and can be used for treating lung cancer and other tumors.

The disclosure relates to methods of delivering a gene therapy agent to a subject, treating an individual in need of a gene therapy agent, increasing expression of a gene therapy agent, reducing an immune response to a gene therapy agent, and preventing immune-related adverse events in a subject by administering a gene therapy agent and an IL-2 conjugate to the subject. The IL-2 conjugate has at least one amino acid residue replaced by an unnatural amino acid linked to a conjugating moiety. The disclosure further relates to methods of selecting a subject for treatment with a gene therapy agent and an IL-2 conjugate.

The invention belongs to the field of biological medicine, and relates to a rosmarinic acid and scutellarin compatible composition and application thereof. The invention specifically discloses a rosmarinic acid and scutellarin composition as shown in formulas (I) and (II), and the rosmarinic acid and scutellarin composition is applied to treatment and / or prevention of acute lung injury. The screened rosmarinic acid and scutellarin composition is simple in preparation method, has a potential synergistic treatment effect on acute lung injury, has a remarkable treatment effect on lung functions, alveolar lavage fluid inflammatory factors and serum inflammatory indexes of LPS-induced mouse acute lung injury, and has a good application prospect. And compared with the toxic and side effects of dexamethasone on reducing body weight, the dexamethasone shows good safety, and meanwhile, the dexamethasone shows a remarkable inhibition effect on secretion of primary peritoneal macrophages NO, TNF-alpha and IL-6 in vitro. In conclusion, the rosmarinic acid and scutellarin composition can be in the form of a single composition or a medicinal composition, and has potential application value in treatment of acute lung injury and immune-related diseases. # imgabs0 #

The invention relates to the technical field of chemical toxicology, in particular to an evaluation method for comprehensively analyzing the immune induction effect of a plasticizer by using caenorhabditis elegans, according to the evaluation method, a mother worm breeding mode is changed to replace a lysis solution to synchronize nematodes, experimental interference is reduced, the result accuracy is improved, monitoring indexes are newly increased, intestinal injuries and in-vivo bacterial indexes are increased, and the evaluation method is suitable for comprehensive analysis of the immune induction effect of the plasticizer. The evaluation is more accurate and reliable by combining oxidative stress indexes and performing two-dimensional comprehensive evaluation from an intestinal immune defense line and oxidative stress, and by drawing a multi-index monitoring shape graph, adopting a comprehensive biomarker response index analysis method and associating immune-related representative indexes, the evaluation accuracy is improved. According to the method, the change of each index and the immunity intensity on the caenorhabditis elegans under different exposure conditions are intuitively presented, the immune defense effect of the caenorhabditis elegans under the stress of the plasticizer can be quickly and effectively evaluated without transcriptome and metabonomics, and efficient evaluation is realized.

The present disclosure generally relates to compositions and methods for predicting or diagnosing immune-related adverse events (irAE) before, during, or after immune checkpoint inhibitor (ICI) treatment in a subject with cancer. The method includes assessment of immune cell types, cytokines, autoantibodies or any combination thereof.

The present disclosure provides chimeric antigen receptor (CAR) molecule specific for B cell maturation antigen (BC-MA), compositions and methods for treating immune-related disorders, specifically, plasma cell pathologies such as multiple myeloma (MM).

The invention discloses a pig immunity-related SNP (Single Nucleotide Polymorphism) site molecular marker and application, and belongs to the related field of pig stress resistance. The marker has three single nucleotide polymorphic sites in total, the three single nucleotide polymorphic sites are respectively positioned at nucleic acid sites at 48950343, 48950346 and 48950523 of a chromosome 2 of a pig reference genome Sscrofa11.1, are respectively subjected to A48950343G, G48950346C and A48950523G single base mutation, are contained at an LYVE1 gene exon and are subjected to non-synonymous mutation, and a nucleotide sequence is shown as SEQ ID NO.1. The invention further discloses a detection method of the single nucleotide polymorphic sites of the pig reference genome Sscrofa11.1 and a detection method of the single nucleotide polymorphic sites of the pig reference genome Sscrofa11.1. The identified sites of the SNP related to the immune index characters can be used as molecular markers for pig excellent character breeding, and the genetic progress of pig disease-resistant breeding is facilitated.

This invention relates to the field of molecular biology, specifically to the application of miR-193a-5p antagonists in the preparation of drugs for treating immune-associated pneumonia, the sequence of which is shown in SEQ ID NO: 1. This invention experimentally demonstrates for the first time that miR-193a-5p expression is significantly upregulated in an immune-associated pneumonia model, and that the use of its specific antagonist can effectively alleviate pneumonia symptoms; therefore, miR-193a-5p antagonists can be used as active ingredients in the preparation of drugs for treating immune-associated pneumonia caused by immune checkpoint inhibitors.

The invention discloses a PD-L1 monoclonal antibody delivery system as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: coupling amino groups of BPA-PEG9 and a PD-L1 monoclonal antibody through NHS (N-hydroxysuccinimide) esterification to form BPA6-aPDL1; the preparation method comprises the following steps: grafting a glucose derivative maltomimetic acid MA of o-benzene dihydroxyl to a lipid-like amphiphilic molecule PEG (Polyethylene Glycol) (1.5 k-DSPE) through an amido bond to form MA4-PEG (1.5 k-DSPE), namely MA4-PD; then, the BPA6-aPDL1 reacts with the MA4-PD through a boric acid ester bond, and finally, the delivery system MB-aPDL1 is formed. The delivery system not only can successfully deliver the PD-L1 to a tumor site across a blood brain barrier, but also can accurately release the PD-L1 monoclonal antibody, so that the PD-L1 monoclonal antibody is only enriched in a tumor region, the residence time of the antibody is prolonged, the tumor anchoring capability of the antibody is improved, and the occurrence of immune-related adverse events is remarkably reduced.

Provided herein are methods of predicting the risk of immune checkpoint inhibitor (ICI) therapy to elicit immune-related adverse events (irAE). The methods include classifying a T cell receptor beta gene as a productive TCR beta gene or a repaired TCR beta gene, and calculating a Tolerance Fractional (TF) score. Classification of the TCR [beta] gene indicates the relative presence of non-tolerant T cells that may recognize autoantigens after receiving ICI treatment. The relative presence of non-tolerant T cells indicates the risk of the occurrence of irAE.